AnaptysBio (NASDAQ:ANAB) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

AnaptysBio (NASDAQ:ANAB) had its price target upped by equities research analysts at JPMorgan Chase & Co. from $36.00 to $42.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 177.23% from the company’s current price.

Other analysts also recently issued reports about the company. HC Wainwright restated a “neutral” rating and issued a $22.00 price objective on shares of AnaptysBio in a report on Tuesday. Wedbush reissued an “outperform” rating and issued a $40.00 price target on shares of AnaptysBio in a research note on Wednesday, February 12th. Wells Fargo & Company lifted their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Wolfe Research began coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They set an “outperform” rating and a $25.00 target price for the company. Finally, Truist Financial dropped their price target on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.11.

AnaptysBio Stock Down 0.7 %

Shares of ANAB stock traded down $0.10 during mid-day trading on Wednesday, reaching $15.15. 15,979 shares of the stock traded hands, compared to its average volume of 1,049,424. The company has a market cap of $461.00 million and a price-to-earnings ratio of -2.50. The stock’s fifty day simple moving average is $16.05 and its two-hundred day simple moving average is $24.32. AnaptysBio has a 1-year low of $12.21 and a 1-year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($1.61) by $0.89. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $43.11 million for the quarter, compared to the consensus estimate of $10.17 million. On average, equities research analysts anticipate that AnaptysBio will post -6.08 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In other news, Director Ecor1 Capital, Llc acquired 6,646 shares of AnaptysBio stock in a transaction on Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, with a total value of $86,065.70. Following the completion of the purchase, the director now owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its holdings in AnaptysBio by 131.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock worth $36,000 after buying an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of AnaptysBio in the 4th quarter worth about $40,000. AlphaQuest LLC lifted its position in AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 4,237 shares in the last quarter. Virtus ETF Advisers LLC boosted its stake in AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 936 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in AnaptysBio by 1,585.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 5,360 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.